234 related articles for article (PubMed ID: 33115780)
1. Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer.
Gay MD; Safronenka A; Cao H; Liu FH; Malchiodi ZX; Tucker RD; Kroemer A; Shivapurkar N; Smith JP
Cancer Prev Res (Phila); 2021 Jan; 14(1):17-30. PubMed ID: 33115780
[TBL] [Abstract][Full Text] [Related]
2. A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
Tucker RD; Ciofoaia V; Nadella S; Gay MD; Cao H; Huber M; Safronenka A; Shivapurkar N; Kallakury B; Kruger AJ; Kroemer AHK; Smith JP
Dig Dis Sci; 2020 Jan; 65(1):189-203. PubMed ID: 31297627
[TBL] [Abstract][Full Text] [Related]
3. Implicating the cholecystokinin B receptor in liver stem cell oncogenesis.
Gay MD; Drda JC; Chen W; Huang Y; Yassin AA; Duka T; Fang H; Shivapurkar N; Smith JP
Am J Physiol Gastrointest Liver Physiol; 2024 Mar; 326(3):G291-G309. PubMed ID: 38252699
[TBL] [Abstract][Full Text] [Related]
4. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
[TBL] [Abstract][Full Text] [Related]
5. Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma.
Shivapurkar N; Gay MD; He AR; Chen W; Golnazar S; Cao H; Duka T; Kallakury B; Vasudevan S; Smith JP
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835036
[TBL] [Abstract][Full Text] [Related]
6. Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome.
Gay MD; Cao H; Shivapurkar N; Dakshanamurthy S; Kallakury B; Tucker RD; Kwagyan J; Smith JP
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163821
[TBL] [Abstract][Full Text] [Related]
7. Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non-alcoholic Steatohepatitis.
Rabiee A; Gay MD; Shivapurkar N; Cao H; Nadella S; Smith CI; Lewis JH; Bansal S; Cheema A; Kwagyan J; Smith JP
Clin Pharmacol Ther; 2022 Dec; 112(6):1271-1279. PubMed ID: 36087237
[TBL] [Abstract][Full Text] [Related]
8. Cholecystokinin protects mouse liver against ischemia and reperfusion injury.
Zhang Y; Zhu J; Guo L; Zou Y; Wang F; Shao H; Li J; Deng X
Int Immunopharmacol; 2017 Jul; 48():180-186. PubMed ID: 28521244
[TBL] [Abstract][Full Text] [Related]
9. Paracrine activation of hepatic stellate cells in platelet-derived growth factor C transgenic mice: evidence for stromal induction of hepatocellular carcinoma.
Wright JH; Johnson MM; Shimizu-Albergine M; Bauer RL; Hayes BJ; Surapisitchat J; Hudkins KL; Riehle KJ; Johnson SC; Yeh MM; Bammler TK; Beyer RP; Gilbertson DG; Alpers CE; Fausto N; Campbell JS
Int J Cancer; 2014 Feb; 134(4):778-88. PubMed ID: 23929039
[TBL] [Abstract][Full Text] [Related]
10. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
Grohmann M; Wiede F; Dodd GT; Gurzov EN; Ooi GJ; Butt T; Rasmiena AA; Kaur S; Gulati T; Goh PK; Treloar AE; Archer S; Brown WA; Muller M; Watt MJ; Ohara O; McLean CA; Tiganis T
Cell; 2018 Nov; 175(5):1289-1306.e20. PubMed ID: 30454647
[TBL] [Abstract][Full Text] [Related]
11. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
Kawakubo M; Tanaka M; Ochi K; Watanabe A; Saka-Tanaka M; Kanamori Y; Yoshioka N; Yamashita S; Goto M; Itoh M; Shirakawa I; Kanai S; Suzuki H; Sawada M; Ito A; Ishigami M; Fujishiro M; Arima H; Ogawa Y; Suganami T
Sci Rep; 2020 Jan; 10(1):983. PubMed ID: 31969650
[TBL] [Abstract][Full Text] [Related]
12. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation.
Afrin R; Arumugam S; Rahman A; Wahed MI; Karuppagounder V; Harima M; Suzuki H; Miyashita S; Suzuki K; Yoneyama H; Ueno K; Watanabe K
Int Immunopharmacol; 2017 Mar; 44():174-182. PubMed ID: 28110063
[TBL] [Abstract][Full Text] [Related]
13. Targeting of cholecystokinin B/gastrin receptor in colonic, pancreatic and hepatocellular carcinoma cell lines.
Savage K; Waller HA; Stubbs M; Khan K; Watson SA; Clarke PA; Grimes S; Michaeli D; Dhillon AP; Caplin ME
Int J Oncol; 2006 Dec; 29(6):1429-35. PubMed ID: 17088981
[TBL] [Abstract][Full Text] [Related]
14. A Mouse Model of Hepatocellular Carcinoma Induced by Streptozotocin and High-Fat Diet.
Motiño O; Li S; Lambertucci F; Anagnostopoulos G; Montégut L; Nogueira-Recalde U; Chen H; Maiuri MC; Kroemer G; Martins I
Methods Mol Biol; 2024; 2769():67-75. PubMed ID: 38315389
[TBL] [Abstract][Full Text] [Related]
15. Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis.
Kojima M; Takahashi H; Kuwashiro T; Tanaka K; Mori H; Ozaki I; Kitajima Y; Matsuda Y; Ashida K; Eguchi Y; Anzai K
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32785012
[TBL] [Abstract][Full Text] [Related]
16. Dietary fat stimulates pancreatic cancer growth and promotes fibrosis of the tumor microenvironment through the cholecystokinin receptor.
Nadella S; Burks J; Al-Sabban A; Inyang G; Wang J; Tucker RD; Zamanis ME; Bukowski W; Shivapurkar N; Smith JP
Am J Physiol Gastrointest Liver Physiol; 2018 Nov; 315(5):G699-G712. PubMed ID: 29927319
[TBL] [Abstract][Full Text] [Related]
17. Peretinoin, an acyclic retinoid, suppresses steatohepatitis and tumorigenesis by activating autophagy in mice fed an atherogenic high-fat diet.
Okada H; Takabatake R; Honda M; Takegoshi K; Yamashita T; Nakamura M; Shirasaki T; Sakai Y; Shimakami T; Nagata N; Takamura T; Tanaka T; Kaneko S
Oncotarget; 2017 Jun; 8(25):39978-39993. PubMed ID: 28591717
[TBL] [Abstract][Full Text] [Related]
18. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
19. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice.
Takatani N; Kono Y; Beppu F; Okamatsu-Ogura Y; Yamano Y; Miyashita K; Hosokawa M
Biochem Biophys Res Commun; 2020 Jul; 528(2):305-310. PubMed ID: 32475638
[TBL] [Abstract][Full Text] [Related]
20. Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice.
Smith JP; Cooper TK; McGovern CO; Gilius EL; Zhong Q; Liao J; Molinolo AA; Gutkind JS; Matters GL
Pancreas; 2014 Oct; 43(7):1050-9. PubMed ID: 25058882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
